C

ChemoCentryx Inc
F:2CX

Watchlist Manager
ChemoCentryx Inc
F:2CX
Watchlist
Price: 51.89 EUR
Market Cap: 3.7B EUR

Net Margin
ChemoCentryx Inc

-357%
Current
-239%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-357%
=
Net Income
-133.1m
/
Revenue
37.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
ChemoCentryx Inc
F:2CX
3.7B EUR
-357%
IL
Can Fite Biopharma Ltd
TASE:CANF
17.7m ILS
-1 456%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
383.1B USD
4%
US
Amgen Inc
NASDAQ:AMGN
177.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.5B USD
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD
32%
AU
CSL Ltd
ASX:CSL
85.1B AUD
19%
NL
argenx SE
XBRU:ARGX
43.3B EUR
43%
No Stocks Found

ChemoCentryx Inc
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

Nestled in the bustling hub of biopharmaceutical innovation, ChemoCentryx Inc. has carved out a unique niche in the world of healthcare, focusing on the development of orally administered therapeutics to combat autoimmune diseases, inflammatory disorders, and cancer. Founded in 1996, this biotechnology pioneer operates with a deep-seated commitment to harnessing the science of chemokine receptors and their associated pathways. ChemoCentryx's core strategy revolves around precision medicine, aimed at modulating the immune system to treat vexing diseases while minimizing traditional treatment pitfalls. By targeting specific pathways involved in the body's inflammatory response, the company endeavors to offer therapies that not only alleviate symptoms but potentially alter the course of diseases. Central to ChemoCentryx's business model is its flagship product, TAVNEOS® (avacopan), approved in several markets for the management of ANCA-associated vasculitis, a rare and potentially life-threatening disease. This product exemplifies their approach: focusing on challenging therapeutic areas with significant unmet medical needs. Revenue streams are predominantly generated through the commercialization of such novel drugs, supplemented by strategic partnerships with major pharmaceutical companies. These alliances not only enhance their research capabilities but also broaden their potential market reach. By combining cutting-edge science with strategic business acumen, ChemoCentryx stands at the frontier of fostering innovative solutions to some of the most daunting health challenges.

2CX Intrinsic Value
Not Available
C
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-357%
=
Net Income
-133.1m
/
Revenue
37.3m
What is the Net Margin of ChemoCentryx Inc?

Based on ChemoCentryx Inc's most recent financial statements, the company has Net Margin of -357%.

Back to Top